McIlrath & Eck’s Clovis Oncology, Inc. CLVS Stock Holding History

McIlrath & Eck’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$1K	–	928
2022 Q3	$1K	Hold	500	–	–	﹤0.01%	830
2022 Q2	$1K	Hold	500	–	–	﹤0.01%	819
2022 Q1	$1K	Hold	500	–	–	﹤0.01%	799
2021 Q4	$1K	Hold	500	–	–	﹤0.01%	788
2021 Q3	$2K	Buy	+500	New	+$2.41K	﹤0.01%	745

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

McIlrath & Eck's CLVS Position: Q4 2022 in Review

McIlrath & Eck sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 500 shares — an estimated $1K sold.

McIlrath & Eck first reported a position in CLVS in Q3 2021 and held it in 5 quarters. The position peaked at $2K in Q3 2021. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

McIlrath & Eck reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
McIlrath & Eck sold 500 Clovis Oncology, Inc. shares in Q4 2022, an estimated $1K.
McIlrath & Eck first reported a position in Clovis Oncology, Inc. in Q3 2021 and held it in 5 quarters.
McIlrath & Eck's Clovis Oncology, Inc. position peaked at $2K in Q3 2021.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on McIlrath & Eck's 13F filing for Q4 2022, filed 15 Feb 2023.